We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
+10.49%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$11.9B
AUM Growth
+$2.55B
(+27%)
Cap. Flow
+$1.81B
Cap. Flow
% of AUM
15.19%
Top 10 Holdings %
Top 10 Hldgs %
28.34%
Holding
1,181
New
44
Increased
774
Reduced
301
Closed
61
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$294M |
| 2 |
Apple
AAPL
|
+$74.6M |
| 3 |
iShares China Large-Cap ETF
FXI
|
+$68.1M |
| 4 |
Tesla
TSLA
|
+$64.9M |
| 5 |
Microsoft
MSFT
|
+$51.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microchip Technology
MCHP
|
+$12.3M |
| 2 |
VanEck Junior Gold Miners ETF
GDXJ
|
+$8.37M |
| 3 |
CLR
CONTINENTAL RESOURCES INC.
CLR
|
+$7.53M |
| 4 |
ASML
ASML
|
+$7.05M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$6.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 34.81% |
| 2 | Financials | 13.96% |
| 3 | Healthcare | 11.37% |
| 4 | Energy | 7.72% |
| 5 | Consumer Discretionary | 3.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Xcel Energy
XEL
$48.8B
| $6.99M | 0.06% |
99,757
-12,298
| -11% | -$818K |
|
302
Charter Communications
CHTR
$17.3B
| $6.97M | 0.06% |
20,568
-364
| -2% | -$128K |
|
303
Cintas
CTAS
$81.9B
| $6.9M | 0.06% |
61,092
-16,424
| -21% | -$1.78M |
|
|
DVAX
304
DELISTED
Dynavax Technologies
DVAX
| $6.88M | 0.06% |
646,887
+52,070
| +9% | +$605K |
|
305
Zoom
ZM
$28.2B
| $6.86M | 0.06% |
101,242
-16,608
| -14% | -$1.26M |
|
306
Howmet Aerospace
HWM
$113B
| $6.85M | 0.06% |
173,834
+37,081
| +27% | +$1.35M |
|
307
Editas Medicine
EDIT
$396M
| $6.84M | 0.06% |
770,952
+333,191
| +76% | +$3.66M |
|
|
IMGN
308
DELISTED
Immunogen Inc
IMGN
| $6.79M | 0.06% |
1,368,213
+420,762
| +44% | +$2.28M |
|
309
MannKind Corp
MNKD
$1.21B
| $6.76M | 0.06% |
1,282,197
-173,421
| -12% | -$710K |
|
310
Syndax Pharmaceuticals
SNDX
$1.69B
| $6.74M | 0.06% |
264,762
+118,380
| +81% | +$2.76M |
|
311
Travere Therapeutics
TVTX
$5.2B
| $6.72M | 0.06% |
319,454
+113,687
| +55% | +$2.41M |
|
312
CRISPR Therapeutics
CRSP
$4.73B
| $6.69M | 0.06% |
164,652
+61,206
| +59% | +$3.25M |
|
313
Veracyte
VCYT
$3.7B
| $6.69M | 0.06% |
281,728
-63,889
| -18% | -$1.48M |
|
314
Textron
TXT
$14.7B
| $6.68M | 0.06% |
94,334
+16,072
| +21% | +$1.09M |
|
315
Fidelity National Information Services
FIS
$23.1B
| $6.67M | 0.06% |
98,262
+15,827
| +19% | +$1.12M |
|
316
CoStar Group
CSGP
$11.7B
| $6.66M | 0.06% |
86,220
+73,605
| +583% | +$5.75M |
|
317
Old Dominion Freight Line
ODFL
$44.1B
| $6.65M | 0.06% |
46,902
-16,682
| -26% | -$2.37M |
|
318
Monster Beverage
MNST
$94.3B
| $6.65M | 0.06% |
130,950
-44,954
| -26% | -$2.18M |
|
319
Dollar Tree
DLTR
$24.4B
| $6.6M | 0.06% |
46,641
-11,023
| -19% | -$1.64M |
|
320
PACCAR
PCAR
$69.8B
| $6.59M | 0.06% |
99,953
-35,194
| -26% | -$2.3M |
|
321
Align Technology
ALGN
$12.1B
| $6.58M | 0.06% |
31,178
-1,775
| -5% | -$355K |
|
322
Celldex Therapeutics
CLDX
$2.99B
| $6.39M | 0.05% |
143,331
-64,362
| -31% | -$2.3M |
|
323
Datadog
DDOG
$95.4B
| $6.37M | 0.05% |
86,682
-8,531
| -9% | -$666K |
|
324
Kraft Heinz
KHC
$30.7B
| $6.35M | 0.05% |
155,996
-60,279
| -28% | -$2.29M |
|
325
Electronic Arts
EA
$53B
| $6.31M | 0.05% |
51,635
-11,430
| -18% | -$1.44M |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q4 2022 Portfolio in Review
As of Q4 2022, Rafferty Asset Management held 1,181 positions worth $11.9B, up 27% from $9.4B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Rafferty Asset Management deployed $1.81B of net new capital in Q4 2022, opening 44 new positions and adding to 774 existing holdings. Its largest new stake was Akero Therapeutics: 187,799 shares worth $10.3M.
By sector, the portfolio is most concentrated in Technology at 35% of assets, down from 38% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Microchip Technology, an estimated $12.3M trimmed.
- Rafferty Asset Management's largest Q4 2022 buy was Akero Therapeutics: 187,799 shares worth $10.3M.
- Rafferty Asset Management added most to iShares 20+ Year Treasury Bond ETF in Q4 2022, an estimated $294M increase.
- Rafferty Asset Management's biggest Q4 2022 reduction was Microchip Technology, cutting an estimated $12.3M.
- Rafferty Asset Management fully exited CONTINENTAL RESOURCES INC. in Q4 2022, selling an estimated $7.53M.
- Rafferty Asset Management's ten largest holdings make up 28% of its $11.9B portfolio in Q4 2022.
- Rafferty Asset Management opened 44 new positions and closed 61 in Q4 2022.
- Rafferty Asset Management's portfolio value rose 27% quarter-over-quarter to $11.9B.
Based on Rafferty Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.